Prelude Therapeutics
PRLD
PRLD
55 hedge funds and large institutions have $176M invested in Prelude Therapeutics in 2023 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 25 increasing their positions, 9 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more funds holding
Funds holding: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
2% less capital invested
Capital invested by funds: $180M → $176M (-$3.42M)
60% less call options, than puts
Call options by funds: $2K | Put options by funds: $5K
Holders
55
Holding in Top 10
–
Calls
$2K
Puts
$5K
Top Buyers
| 1 | +$8.08M | |
| 2 | +$6.27M | |
| 3 | +$5.21M | |
| 4 |
O
OrbiMed
New York
|
+$3.91M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$3.59M |
Top Sellers
| 1 | -$739K | |
| 2 | -$367K | |
| 3 | -$301K | |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$173K |
| 5 |
6CM
683 Capital Management
New York
|
-$163K |